The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L

Eva M Gamper; Francesco Cottone; Kathrin Sommer; Richard Norman; Madeleine King; Massimo Breccia; Giovanni Caocci; Andrea Patriarca; Giuseppe A Palumbo; Reinhard Stauder; Pasquale Niscola; Uwe Platzbecker; Jo Caers; Marco Vignetti; Fabio Efficace

doi:10.1016/j.jclinepi.2021.03.015

The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L

J Clin Epidemiol. 2021 Sep:137:31-44. doi: 10.1016/j.jclinepi.2021.03.015. Epub 2021 Mar 20.

Authors

Affiliations

¹ Innsbruck Institute of Patient-centered Outcome Research (IIPCOR), Innsbruck, Austria. Electronic address: eva.gamper@iipcor.org.
² Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center & Health Outcomes Research Unit, Rome, Italy.
³ School of Public Health, Curtin University, Perth, Australia.
⁴ University of Sydney, School of Psychology, Sydney, NSW, Australia.
⁵ Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.
⁶ Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
⁷ Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
⁸ Dipartimento di Scienze Mediche, Chirurgiche e Tecnologie Avanzate "G.F. Ingrassia", University of Catania, Catania, Italy.
⁹ Department of Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Innsbruck, Austria.
¹⁰ Hematology Unit, Sant'Eugenio Hospital, Rome, Italy.
¹¹ Clinic and Policlinic of Hematology and Cellular Therapy, Hemostaseology, University Hospital Leipzig, Leipzig, Germany.
¹² Department of Hematology, CHU de Liège, University of Liege, Liege, Belgium.

PMID: 33753228
DOI: 10.1016/j.jclinepi.2021.03.015

Abstract

Background: The aim was to investigate the relative validity of the preference-based measure EORTC QLU-C10D in comparison with the EQ-5D-3L in myelodysplastic syndromes (MDS) patients.

Methods: We used data from an international multicentre, observational cohort study of MDS patients. Baseline EORTC QLU-C10D and EQ-5D-3L scores were used and index scores calculated for Italy, Australia, and the UK. Criterion validity was established by Spearman and intraclass correlations (ICC) and Bland-Altman plots. Construct validity was established by the instruments' ability to discriminate known groups, i.e. groups whose health status is expected to differ.

Results: We analyzed data from 619 MDS patients (61.1% male; median age 73.8 years). Correlations between theoretically corresponding domains were largely higher than between unrelated domains. ICCs and Bland-Altman plots indicated moderate to good criterion validity. Ceiling effects were lower for the QLU-C10D (4.7%) than for the EQ-5D-3L (22.6%). The EQ-5D-3L failed to discriminate known-groups in two and the QLU-C10D in one of the comparisons; the QLU-C10D's efficiency in doing so was higher in clinical known-groups. Results were comparable between the countries.

Conclusions: The QLU-C10D may be suitable to generate health utilities for economic research in MDS. Responsiveness and minimal important differences need yet to be established.

Keywords: Cancer-specific preference-based measure; EORTC QLQ-C30; EORTC QLU-C10D; EQ-5D; Sensitivity; Validity.

Publication types

Comparative Study
Multicenter Study
Observational Study

MeSH terms

Aged
Cohort Studies
Female
Humans
Male
Myelodysplastic Syndromes* / diagnosis
Quality of Life*
Reproducibility of Results